Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
Supportive Care in Cancer, 06/21/2012
Clinical Article
Cartoni C et al. – Controlled–release (CR) oxycodone for relief of bortezomib–induced peripheral neuropathy (BIPN)–related pain was effective and well tolerated. The pain control significantly improved also the quality of the daily life functions, which are usually compromised in these suffering patients.
Methods- Forty–six patients (median age, 62 years) affected by myeloma and lymphoma, complaining of BIPN–related pain of moderate–to–severe intensity and unresponsive to previous analgesic treatments, were treated with CR oxycodone.
- The intensity of continuous and brief pain (BP) along with interference of pain with the common daily dimensions of feeling and function were evaluated by using an 11–point numerical rating scale (NRS); a global patient evaluation of efficacy was also performed.
- The daily average dose of CR oxycodone administered was 28.46 mg (range, 20–80 mg).
- The pain intensity decreased from a mean NRS value of 7.6 at baseline to 1.3 on day 14.
- The frequency of BP was reduced from 61 to 47 % of patients and its intensity from 7.4 to 3.1 NRS score.
- A similar trend to decreasing values was observed for all the daily life functions.
- Slight– or mild–intensity side effects were observed in 23 patients (51 %).
- At the end of the study, 75 % of patients found the treatment effective or very effective.
